Febuxostat 40 mg/day vs placebo
Health related quality of life · people with chronic gout
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Findings
What do systematic reviews say?
480 questions · 484 findings · 52 reviews · Musculoskeletal
No studies found 114 · 23.6%GRADE not reported 24 · 5%Very low 33 · 6.8%Low 145 · 30%Moderate 116 · 24%High 52 · 10.7%
Febuxostat 40 mg/day vs placebo
Serious adverse events · people with chronic gout
Febuxostat 40 mg/day probably leads to higher serious Adverse Events compared with placebo (moderate certainty).
1 finding from 1 review
- RR 1 [0, 0]1 study · 75 participantsModerate
Febuxostat 40 mg/day vs placebo
Withdrawals due to adverse events · people with chronic gout
Febuxostat 40 mg/day showed no clear difference in discontinuations due to adverse events compared with placebo (moderate certainty).
1 finding from 1 review
- RR 1 [0.07, 15.8]1 study · 75 participantsModerate
Febuxostat 80 mg/day vs placebo
Acute gout attacks · people with chronic gout
Febuxostat 80 mg/day showed no clear difference in incidence of gout flares compared with placebo (low certainty).
1 finding from 1 review
- RR 1.32 [0.96, 1.8]2 studies · 474 participantsLow
Febuxostat 80 mg/day vs placebo
Serum uric acid <6.0 mg/dL at final visit · people with chronic gout
Febuxostat 80 mg/day may leads to higher serum uric acid <6.0 mg/dL at final visit compared with placebo (low certainty).
1 finding from 1 review
- RR 68.9 [13.8, 343.9]2 studies · 332 participantsLow
Nefopam 60 mg tds vs placebo
pain ‐ 100mm VAS mm. Scale from: 0 to 100. · patients with pain management in rheumatoid arthritis
1 finding from 1 review
- no estimate extracted2 studies · 48 participantsLow
Nefopam 60 mg tds vs placebo
Withdrawals due to adverse events · patients with pain management in rheumatoid arthritis
Nefopam 60 mg tds showed no clear difference in withdrawal Due to adverse events compared with placebo (moderate certainty).
1 finding from 1 review
- RR 11 [0.64, 189.65]1 study · 54 participantsModerate
Nefopam 60 mg tds vs placebo
Total adverse events · patients with pain management in rheumatoid arthritis
Nefopam 60 mg tds may leads to higher total adverse events compared with placebo (low certainty).
1 finding from 1 review
- RR 4.11 [1.58, 10.69]2 studies · 104 participantsLow
Capsaicin 0.025% vs placebo
Pain (% reduction from baseline) VAS 100mm · patients with Knee pain in patients with rheumatoid arthritis
2 findings from 1 review
- no estimate extracted1 study · 30 participantsLow
- no estimate extracted1 study · 29 participantsLow
Oromucosal cannabis (Sativex) vs placebo
Pain at present McGill short form questionnaire ‐ Verbal rating scale (0‐5) · patients with pain management in rheumatoid arthritis
1 finding from 1 review
- no estimate extracted1 study · 58 participantsLow
Oromucosal cannabis (Sativex) vs placebo
Quality of sleep · patients with pain management in rheumatoid arthritis
1 finding from 1 review
- no estimate extracted1 study · 58 participantsLow
Oromucosal cannabis (Sativex) vs placebo
Withdrawals due to adverse events · patients with pain management in rheumatoid arthritis
Oromucosal cannabis (Sativex) showed no clear difference in withdrawal due to adverse events compared with placebo (low certainty).
1 finding from 1 review
- RR 0.13 [0.01, 2.39]1 study · 58 participantsLow
Oromucosal cannabis (Sativex) vs placebo
Total adverse events · patients with pain management in rheumatoid arthritis
Oromucosal cannabis (Sativex) may leads to higher total adverse events compared with placebo (low certainty).
1 finding from 1 review
- RR 1.82 [1.1, 3]1 study · 58 participantsLow
MAOIs vs placebo
Pain (VAS) VAS from: 0 to 10 · patients with fibromyalgia
1 finding from 1 review
- Monoamine oxidase inhibitors (MAOIs) for fibromyalgia syndrome 2012 · Cochrane Headline outcomes onlyno estimate extracted2 studies · 121 participantsLow
MAOIs vs placebo
Tender points Tender point score and number of tender points · patients with fibromyalgia
1 finding from 1 review
- Monoamine oxidase inhibitors (MAOIs) for fibromyalgia syndrome 2012 · Cochrane Headline outcomes onlyno estimate extracted2 studies · 121 participantsLow
MAOIs vs placebo
Global assessment (by patient) VAS from: 0 to 10 · patients with fibromyalgia
1 finding from 1 review
- Monoamine oxidase inhibitors (MAOIs) for fibromyalgia syndrome 2012 · Cochrane Headline outcomes onlyno estimate extracted2 studies · 121 participantsLow
MAOIs vs placebo
Physical function · patients with fibromyalgia
The review found no eligible studies for this question.
1 finding from 1 review
- Monoamine oxidase inhibitors (MAOIs) for fibromyalgia syndrome 2012 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
MAOIs vs placebo
Withdrawals due to adverse events · patients with fibromyalgia
1 finding from 1 review
- Monoamine oxidase inhibitors (MAOIs) for fibromyalgia syndrome 2012 · Cochrane Headline outcomes onlyno estimate extracted2 studies · 149 participantsLow
MAOIs vs placebo
Nausea and vomiting · patients with fibromyalgia
1 finding from 1 review
- Monoamine oxidase inhibitors (MAOIs) for fibromyalgia syndrome 2012 · Cochrane Headline outcomes onlyno estimate extracted1 study · 89 participantsLow
MAOIs vs placebo
Sleep disturbance (adverse event) · patients with fibromyalgia
The review found no eligible studies for this question.
1 finding from 1 review
- Monoamine oxidase inhibitors (MAOIs) for fibromyalgia syndrome 2012 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found